Search Within

Parisa Momtaz

Formats
  1. Journal Article (27)
  2. Meeting Abstract (22)
  3. Book Section (4)
  4. Research Letter (1)
Groups
  1. Department of Medicine (54)
  2. Melanoma Disease Management Team (54)
  3. Melanoma and Immunotherapeutics Service (54)
  4. Solid Tumor Oncology Division (54)
  5. Survivorship Research (54)
  6. Weinberg Fellows (54)

More Groups

People
  1. Michael Postow (36)
  2. Alexander Shoushtari (32)
  3. Paul Chapman (31)
  4. Jedd Wolchok (29)
  5. Margaret Callahan (29)
  6. Katherine Panageas (25)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (5)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Pocket Oncology (4)
  3. Clinical Cancer Research (3)
  4. Nature (3)
  5. JAMA Oncology (2)
  6. Oncotarget (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Oxford University Press (4)
  3. Wolters Kluwer Health | Lippincott Williams & Wilkins (4)
  4. American Association for Cancer Research (3)
  5. Nature Publishing Group (3)
  6. Wiley Blackwell (3)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia
    Journal Article

    Smithy, J. W.; Pianko, M. J.; Maher, C.; Postow, M. A.; Shoushtari, A. N.; Momtaz, P.; Chapman, P. B.; Wolchok, J. D.; Park, J. H.; Callahan, M. K.
    Journal of Immunotherapy (2021)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A prospective, phase 1 trial of nivolumab, ipilimumab, and radiotherapy in patients with advanced melanoma
    Journal Article

    Postow, M. A.; Knox, S. J.; Goldman, D. A.; Elhanati, Y.; Mavinkurve, V.; Wong, P.; Halpenny, D.; Reddy, S. K.; Vado, K.; McCabe, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade
    Journal Article

    Warner, A. B.; Palmer, J. S.; Shoushtari, A. N.; Goldman, D. A.; Panageas, K. S.; Hayes, S. A.; Bajwa, R.; Momtaz, P.; Callahan, M. K.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade
    Journal Article

    Bello, D. M.; Panageas, K. S.; Hollmann, T.; Shoushtari, A. N.; Momtaz, P.; Chapman, P. B.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Brady, M. S.; more...
    Annals of Surgical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save